BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9-16. [PMID: 21547142 DOI: 10.4161/derm.2.1.12490] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Chen WT, Chi CC. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;. [PMID: 31290938 DOI: 10.1001/jamadermatol.2019.0891] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
2 Rondags A, van Straalen KR, van Hasselt JR, Janse IC, Ardon CB, Vossen ARJV, Prens EP, van der Zee HH, Horváth B. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol 2019;180:1214-20. [PMID: 30512186 DOI: 10.1111/bjd.17508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 González-López MA, Hernández JL, Lacalle M, Mata C, López-Escobar M, López-Mejías R, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol 2016;75:329-35. [PMID: 27287248 DOI: 10.1016/j.jaad.2016.03.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
4 Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, Li W, Janjetovic Z, Postlethwaite A, Zouboulis CC, Tuckey RC. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol 2013;137:107-23. [PMID: 23435015 DOI: 10.1016/j.jsbmb.2013.02.006] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 25.1] [Reference Citation Analysis]
5 Bettoli V, Ricci M, Zauli S, Virgili A. Hidradenitis suppurativa-acne inversa: a relevant dermatosis in paediatric patients. Br J Dermatol 2015;173:1328-30. [DOI: 10.1111/bjd.13951] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Guenin-Macé L, Morel JD, Doisne JM, Schiavo A, Boulet L, Mayau V, Goncalves P, Duchatelet S, Hovnanian A, Bondet V, Duffy D, Ungeheuer MN, Delage M, Nassif A, Di Santo JP, Demangel C. Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa. JCI Insight 2020;5:140598. [PMID: 32970636 DOI: 10.1172/jci.insight.140598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Dany M, Elston D. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa. J Am Acad Dermatol 2017;77:268-273.e6. [PMID: 28551069 DOI: 10.1016/j.jaad.2017.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
8 Lee J, Kwon H, Jung H, Kim G, Bae J. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 2018;32:1784-90. [DOI: 10.1111/jdv.15071] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 14.7] [Reference Citation Analysis]
9 Tzellos T, Zouboulis C, Gulliver W, Cohen A, Wolkenstein P, Jemec G. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 2015;173:1142-55. [DOI: 10.1111/bjd.14024] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
10 Zouboulis CC, Goyal M. Hidradenitis Suppurativa. In: Orfanos CE, Zouboulis CC, Assaf C, editors. Pigmented Ethnic Skin and Imported Dermatoses. Cham: Springer International Publishing; 2018. pp. 219-28. [DOI: 10.1007/978-3-319-69422-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Paradela S, Rodríguez-Lojo R, Fernández-Torres R, Arévalo P, Fonseca E. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat 2012;23:278-83. [PMID: 22482700 DOI: 10.3109/09546634.2012.683767] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
12 Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17:343-351. [PMID: 26831295 DOI: 10.1007/s11154-016-9328-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 59] [Article Influence: 22.3] [Reference Citation Analysis]
13 Shah A, Alhusayen R, Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res 2017;66:931-45. [PMID: 28656364 DOI: 10.1007/s00011-017-1074-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
14 Campanati A, Orciani M, Sorgentoni G, Consales V, Offidani A, Di Primio R. Pathogenetic Characteristics of Mesenchymal Stem Cells in Hidradenitis Suppurativa. JAMA Dermatol 2018;154:1184-90. [PMID: 30140888 DOI: 10.1001/jamadermatol.2018.2516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
15 Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and polycystic ovarian syndrome: Systematic review and meta-analysis. Australas J Dermatol 2020;61:e28-33. [PMID: 31261440 DOI: 10.1111/ajd.13110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Daxhelet M, Suppa M, Benhadou F, Djamei V, Tzellos T, Ingvarsson G, Boer J, Martorell A, Ingram J, Desai N, Nassif A, Revuz J, Hotz C, Bettoli V, Deckers I, Jemec G, Prens E, Zouboulis C, del Marmol V. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software. J Eur Acad Dermatol Venereol 2016;30:1424-6. [DOI: 10.1111/jdv.13267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
17 Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, Hirata SH, Ramos AMC. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol 2019;94:7-19. [PMID: 31166401 DOI: 10.1590/abd1806-4841.20198607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol 2021;157:924-31. [PMID: 34037678 DOI: 10.1001/jamadermatol.2021.1677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
19 van Rappard DC, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review. J Dermatolog Treat 2013;24:392-404. [PMID: 22397574 DOI: 10.3109/09546634.2012.674193] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
20 Bosnić D, Žarković B, Barešić M, Zarkovic M, Anić B. Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab. Reumatologia 2016;54:321-5. [PMID: 28115784 DOI: 10.5114/reum.2016.64910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S27-35. [PMID: 26470611 DOI: 10.1016/j.jaad.2015.07.055] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 15.6] [Reference Citation Analysis]
22 Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019;33:2131-6. [PMID: 31260574 DOI: 10.1111/jdv.15764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Chang JE, Choi MS. A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders. Int J Mol Sci 2020;21:E8960. [PMID: 33255783 DOI: 10.3390/ijms21238960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J 2014;90:216-21; quiz 220. [PMID: 24567417 DOI: 10.1136/postgradmedj-2013-131994] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 9.1] [Reference Citation Analysis]
25 Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J Am Acad Dermatol 2017;76:54-9. [PMID: 27692736 DOI: 10.1016/j.jaad.2016.07.041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
26 Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis 2019;11:1759720X19895488. [PMID: 31908656 DOI: 10.1177/1759720X19895488] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Wollina U, Koch A, Heinig B, Kittner T, Nowak A. Acne inversa (Hidradenitis suppurativa): A review with a focus on pathogenesis and treatment. Indian Dermatol Online J 2013;4:2-11. [PMID: 23439959 DOI: 10.4103/2229-5178.105454] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
28 Phan K, Ng WHS, Lai B, Garg A, Smith SD. Hidradenitis suppurativa and association with stroke: systematic review and meta-analysis. J Dermatolog Treat 2021;:1-8. [PMID: 34289795 DOI: 10.1080/09546634.2021.1959502] [Reference Citation Analysis]
29 Bató A, Brodszky V, Gergely LH, Gáspár K, Wikonkál N, Kinyó Á, Szabó Á, Beretzky Z, Szegedi A, Remenyik É, Kiss N, Sárdy M, Rencz F. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res 2021;30:1477-90. [PMID: 33534032 DOI: 10.1007/s11136-020-02732-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Duran C, Baumeister A. Recognition, diagnosis, and treatment of hidradenitis suppurativa. JAAPA 2019;32:36-42. [PMID: 31567740 DOI: 10.1097/01.JAA.0000578768.62051.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
31 Fotiadou C, Vakirlis E, Ioannides D. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. Clin Cosmet Investig Dermatol 2016;9:367-72. [PMID: 27799806 DOI: 10.2147/CCID.S93619] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
32 Patil S, Apurwa A, Nadkarni N, Agarwal S, Chaudhari P, Gautam M. Hidradenitis Suppurativa: Inside and Out. Indian J Dermatol 2018;63:91-8. [PMID: 29692449 DOI: 10.4103/ijd.IJD_412_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 González-López MA, Lacalle M, Mata C, López-Escobar M, Corrales A, López-Mejías R, Rueda J, González-Vela MC, González-Gay MA, Blanco R, Hernández JL. Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa. PLoS One 2018;13:e0190568. [PMID: 29300768 DOI: 10.1371/journal.pone.0190568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Marrón SE, Gómez-Barrera M, Tomás-Aragonés L, Díaz Díaz RM, Vilarrasa Rull E, Madrid Álvarez MB, Puig L. Development and Preliminary Validation of the HSQoL-24 Tool to Assess Quality of Life in Patients With Hidradenitis Suppurativa. Actas Dermosifiliogr (Engl Ed) 2019;110:554-60. [PMID: 31023484 DOI: 10.1016/j.ad.2019.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wieland C, Vogl T, Ordelman A, Vloedgraven H, Verwoolde L, Rensen J, Roth J, Boer J, Hessels J. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?: S100A8/A9, a novel biomarker for hidradenitis suppurativa. British Journal of Dermatology 2013;168:1252-8. [DOI: 10.1111/bjd.12234] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
36 Cordero-Ramos J, Merino-Bohórquez V, Delgado-Valverde M, Barros-Tornay R, Cameán-Fenández M, Calleja-Hernández MÁ. Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa. Eur J Hosp Pharm 2020:ejhpharm-2020-002534. [PMID: 33328205 DOI: 10.1136/ejhpharm-2020-002534] [Reference Citation Analysis]
37 Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res. 2017;6:1272. [PMID: 28794864 DOI: 10.12688/f1000research.11337.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
38 Garg A, Hundal J, Strunk A. Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa: A Population-Based Analysis in the United States. JAMA Dermatol. 2018;154:814-818. [PMID: 29800049 DOI: 10.1001/jamadermatol.2018.0878] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
39 Sachdeva M, Shah M, Alavi A. Race-Specific Prevalence of Hidradenitis Suppurativa. J Cutan Med Surg 2021;25:177-87. [DOI: 10.1177/1203475420972348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Tzellos T, Zouboulis CC. Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. Dermatol Ther (Heidelb) 2020;10:63-71. [PMID: 31955366 DOI: 10.1007/s13555-020-00354-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
41 Vankeviciute RA, Polozovaite B, Trapikas J, Raudonis T, Grigaitiene J, Bylaite-Bucinskiene M. A 12-Year Experience of Hidradenitis Suppurativa Management. Adv Skin Wound Care 2019;32:1-7. [PMID: 30570558 DOI: 10.1097/01.ASW.0000549611.06727.52] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zouboulis CC, Nogueira da Costa A, Makrantonaki E, Hou XX, Almansouri D, Dudley JT, Edwards H, Readhead B, Balthasar O, Jemec GBE, Bonitsis NG, Nikolakis G, Trebing D, Zouboulis KC, Hossini AM. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020;34:846-61. [PMID: 31838778 DOI: 10.1111/jdv.16147] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
43 van Rappard DC, Mekkes JR, Tzellos T. Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa. Dermatologic Clinics 2016;34:69-80. [DOI: 10.1016/j.det.2015.08.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
44 Phan K, Huo YR, Charlton O, Smith SD. Hidradenitis Suppurativa and Thyroid Disease: Systematic Review and Meta-Analysis. J Cutan Med Surg 2020;24:23-7. [DOI: 10.1177/1203475419874411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Review of Clinical Immunology 2016;12:1015-26. [DOI: 10.1080/1744666x.2016.1221762] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Abdel Azim AA, Salem RT, Abdelghani R. Combined fractional carbon dioxide laser and long-pulsed neodymium : yttrium-aluminium-garnet (1064 nm) laser in treatment of hidradenitis suppurativa; a prospective randomized intra-individual controlled study. Int J Dermatol 2018;57:1135-44. [DOI: 10.1111/ijd.14075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
47 Grimstad Ø, Tzellos T, Dufour DN, Bremnes Ø, Skoie IM, Snekvik I, Jarnaess E, Kyrgidis A, Ingvarsson G. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol 2019;33:1164-71. [PMID: 30451320 DOI: 10.1111/jdv.15353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
48 Vilanova I, Hernández JL, Mata C, Durán C, García-Unzueta MT, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R, González-López MA. Insulin resistance in hidradenitis suppurativa: a case-control study. J Eur Acad Dermatol Venereol 2018;32:820-4. [PMID: 29485215 DOI: 10.1111/jdv.14894] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
49 Esme P, Akoglu G, Sari O, Caliskan E. Family physicians' awareness and general knowledge of hidradenitis suppurativa: A survey research. Int J Clin Pract 2021;75:e14186. [PMID: 33780110 DOI: 10.1111/ijcp.14186] [Reference Citation Analysis]
50 Preda-Naumescu A, Ahmed HN, Mayo TT, Yusuf N. Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations. Int J Dermatol 2021. [PMID: 33890304 DOI: 10.1111/ijd.15579] [Reference Citation Analysis]
51 Katoulis AC, Liakou AI, Rotsiamis N, Bonovas S, Bozi E, Rallis E, Christodoulou C, Rigopoulos D. Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases. Skin Appendage Disord 2017;3:197-201. [PMID: 29177148 DOI: 10.1159/000475822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
52 Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol 2017;176:1048-55. [DOI: 10.1111/bjd.14976] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
53 O'Sullivan Coyne G, Woodring TS, Lee CR, Chen AP, Kong HH. Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase. J Invest Dermatol 2018;138:979-81. [PMID: 29138057 DOI: 10.1016/j.jid.2017.09.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
54 Hosur V, Skelly DA, Francis C, Low BE, Kohar V, Burzenski LM, Amiji MM, Shultz LD, Wiles MV. Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils. Drug Discov Today 2020;25:1013-25. [PMID: 32387410 DOI: 10.1016/j.drudis.2020.03.018] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Martorell A, García-martínez F, Jiménez-gallo D, Pascual J, Pereyra-rodriguez J, Salgado L, Vilarrasa E. Actualización en hidradenitis supurativa (I): epidemiología, aspectos clínicos y definición de severidad de la enfermedad. Actas Dermo-Sifiliográficas 2015;106:703-15. [DOI: 10.1016/j.ad.2015.06.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
56 Deckers IE, van der Zee HH, Prens EP. Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HS. Curr Derm Rep 2014;3:54-60. [DOI: 10.1007/s13671-013-0064-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
57 González-López MA, Ocejo-Viñals JG, Mata C, Díaz D, Guiral S, Portilla V, Corrales A, González-Vela MC, González-Gay MA, Blanco R, Hernández JL. Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. Postepy Dermatol Alergol 2021;38:450-4. [PMID: 34377127 DOI: 10.5114/ada.2021.107932] [Reference Citation Analysis]
58 Alavi A, Lynde C, Alhusayen R, Bourcier M, Delorme I, George R, Gooderham M, Gulliver W, Kalia S, Marcoux D, Poulin Y. Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. J Cutan Med Surg 2017;21:513-24. [PMID: 28639459 DOI: 10.1177/1203475417716117] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
59 Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. Br J Dermatol 2018;179:260-72. [PMID: 29573406 DOI: 10.1111/bjd.16561] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
60 Gill L, Williams M, Hamzavi I. Update on hidradenitis suppurativa: connecting the tracts. F1000Prime Rep 2014;6:112. [PMID: 25580266 DOI: 10.12703/P6-112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
61 Dauden E, Lazaro P, Aguilar M, Blasco A, Suarez C, Marin I, Queiro R, Bassas-vila J, Martorell A, García-campayo J. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2018;32:129-44. [DOI: 10.1111/jdv.14517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
62 González-lópez MA, Hernández JL, Vilanova I, Mata C, López-escobar M, González-vela MC, López-hoyos M, González-gay MA, Blanco R. Thyroid autoimmunity in patients with hidradenitis suppurativa: a case-control study. Clin Exp Dermatol 2017;42:642-4. [DOI: 10.1111/ced.13153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
63 Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019;11:391-401. [PMID: 31114643 DOI: 10.4254/wjh.v11.i4.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
64 Simpson R. Cardiovascular disease risk factors in patients with hidradenitis suppurativa. Br J Dermatol 2015;173:1118-9. [DOI: 10.1111/bjd.14170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Martorell A, García F, Jiménez-gallo D, Pascual J, Pereyra-rodríguez J, Salgado L, Villarrasa E. Actualización en hidradenitis supurativa (ii): aspectos terapéuticos. Actas Dermo-Sifiliográficas 2015;106:716-24. [DOI: 10.1016/j.ad.2015.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
66 Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, Gu Y, Okun MM, Kerdel F. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol 2014;171:1561-5. [PMID: 24842009 DOI: 10.1111/bjd.13122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
67 Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol 2013;27:1329-35. [PMID: 23437788 DOI: 10.1111/jdv.12116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
68 Esposito C, Del Conte F, Cerulo M, Coppola V, Esposito G, Ricciardi E, Castagnetti M, Fabbrocini G, Escolino M. Pediatric Endoscopic Hidradenitis Treatment: A New Minimally Invasive Treatment for Pediatric Patients with Hidradenitis Suppurativa. J Laparoendosc Adv Surg Tech A 2020;30:464-70. [PMID: 32017645 DOI: 10.1089/lap.2019.0614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Wollina U, Langner D, Heinig B, Nowak A. Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report. Int J Dermatol 2017;56:109-15. [PMID: 27495143 DOI: 10.1111/ijd.13393] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
70 Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, Del Marmol V, Marzano AV, Prens EP, Tzellos T, Zouboulis CC. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol 2021;30 Suppl 1:18-22. [PMID: 34085330 DOI: 10.1111/exd.14339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Marasca C, Annunziata MC, Napolitano M, Fabbrocini G. Unconventional therapies for hidradenitis suppurativa. Expert Review of Clinical Pharmacology 2018;11:879-87. [DOI: 10.1080/17512433.2018.1509706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
72 Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019;33:19-31. [PMID: 30176066 DOI: 10.1111/jdv.15233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 22.3] [Reference Citation Analysis]
73 Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D; French Society of Dermatology and Club Rheumatisms and Inflammation. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016;74:1153-9. [PMID: 26965410 DOI: 10.1016/j.jaad.2016.01.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
74 Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, Fabbrocini G. The pharmacology of antibiotic therapy in hidradenitis suppurativa. Expert Review of Clinical Pharmacology 2020;13:521-30. [DOI: 10.1080/17512433.2020.1762571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
75 Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619-644. [PMID: 25640693 DOI: 10.1111/jdv.12966] [Cited by in Crossref: 453] [Cited by in F6Publishing: 324] [Article Influence: 75.5] [Reference Citation Analysis]
76 Bui T, Silva-hirschberg C, Torres J, Armstrong AW. Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 2018;78:395-402. [DOI: 10.1016/j.jaad.2017.08.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
77 Resnik SR, Geisler EL, Reyes N, Lozano J, Ramirez-Caussade RA, Resnik B. Prevalence and Risk Factors for Anemia in a Population With Hidradenitis Suppurativa. Cureus 2020;12:e12015. [PMID: 33457122 DOI: 10.7759/cureus.12015] [Reference Citation Analysis]
78 Phan K, Tatian A, Woods J, Cains G, Frew JW. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta‐analysis. Int J Dermatol 2019;59:221-8. [DOI: 10.1111/ijd.14697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
79 González-López MA, Vilanova I, Ocejo-Viñals G, Arlegui R, Navarro I, Guiral S, Mata C, Pérez-Paredes MG, Portilla V, Corrales A, González-Vela MC, González-Gay MA, Blanco R, Hernández JL. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Arch Dermatol Res 2020;312:595-600. [PMID: 31786710 DOI: 10.1007/s00403-019-02018-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol. 2014;32:397-408. [PMID: 24767187 DOI: 10.1016/j.clindermatol.2013.11.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
81 Choi E, Cook AR, Chandran NS. Hidradenitis Suppurativa: An Asian Perspective from a Singaporean Institute. Skin Appendage Disord 2018;4:281-5. [PMID: 30410897 DOI: 10.1159/000481836] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
82 Fauconier M, Reguiai Z, Barbe C, Colosio A, Eschard J, Salmon J, Direz G. Association between hidradenitis suppurativa and spondyloarthritis. Joint Bone Spine 2018;85:593-7. [DOI: 10.1016/j.jbspin.2017.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
83 Cices A, Ibler E, Majewski S, Huynh T, Sable KA, Brieva J, West DP, Nardone B. Hidradenitis suppurativa association at the time of, or subsequent to, diagnosis of inflammatory bowel disease in a large U.S. patient population. J Eur Acad Dermatol Venereol 2017;31:e311-2. [PMID: 28000245 DOI: 10.1111/jdv.14097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 2019;81:76-90. [PMID: 30872156 DOI: 10.1016/j.jaad.2019.02.067] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 38.5] [Reference Citation Analysis]
85 Verdelli A, Antiga E, Bonciani D, Bonciolini V, Volpi W, Caproni M. A fatal case of hidradenitis suppurativa associated with sepsis and squamous cell carcinoma. Int J Dermatol 2016;55:e52-3. [DOI: 10.1111/ijd.13006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
86 Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC. Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord 2016;17:335-41. [DOI: 10.1007/s11154-016-9366-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
87 Fabbrocini G, Ruocco E, De Vita V, Monfrecola G. Squamous cell carcinoma arising in long-standing hidradenitis suppurativa: An overlooked facet of the immunocompromised district. Clin Dermatol 2017;35:225-7. [PMID: 28274364 DOI: 10.1016/j.clindermatol.2016.10.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
88 Matusiak Ł. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol 2020;183:e171-7. [PMID: 29744872 DOI: 10.1111/bjd.16603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
89 Boer J, Nazary M, Riis PT. The Role of Mechanical Stress in Hidradenitis Suppurativa. Dermatologic Clinics 2016;34:37-43. [DOI: 10.1016/j.det.2015.08.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
90 Fanning E, O'Shea D. Genetics and the metabolic syndrome. Clin Dermatol 2018;36:9-13. [PMID: 29241759 DOI: 10.1016/j.clindermatol.2017.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
91 Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2016;30:989-94. [PMID: 26201313 DOI: 10.1111/jdv.13216] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
92 Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017;177:1401-9. [PMID: 28636793 DOI: 10.1111/bjd.15748] [Cited by in Crossref: 117] [Cited by in F6Publishing: 89] [Article Influence: 29.3] [Reference Citation Analysis]
93 Boo M, Eva L, Kellow M, Scurry J. Vulval squamous cell carcinoma arising from hidradenitis suppurrativa. BMJ Case Rep 2021;14:e241075. [PMID: 34130973 DOI: 10.1136/bcr-2020-241075] [Reference Citation Analysis]